Antithrombotisches Management nach akutem oder chronischem Koronarsyndrom

Zusammenfassung

Nach akutem oder chronischem Koronarsyndrom mit Koronarintervention ist eine antithrombotische Therapie mit dualer Plättchenhemmung erforderlich. Die Intensität und Dauer der Therapie unterscheiden sich je nach Indikation. Für besondere Situationen mit erhöhtem ischämischem Risiko oder erhöhtem Blutungsrisiko liegen Studiendaten vor, auf deren Basis fundierte Entscheidungen zur Intensivierung oder auch zur Deeskalation der Standardtherapie getroffen werden können, um das Nutzen-Risiko-Verhältnis zu optimieren.

Abstract

After an acute coronary syndrome or after coronary intervention for chronic coronary syndrome dual antiplatelet therapy (DAPT) is necessary. Intensity and duration of DAPT are dependent on the respective indication. For clinical scenarios with increased ischemic risk or high bleeding risk clinical trial have been performed. Based on these data decisions for either intensified antithrombotic therapy or de-escalation strategies may be considered to optimise the risk/benefit ratio.

Schlüsselwörter

akutes Koronarsyndrom - Koronarintervention - antithrombotische Therapie

Keywords

acute coronary syndrome - coronary intervention - antithrombotic therapy

• Literatur

• 1 Schomig A, Neumann FJ, Kastrati A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089
• 2 Collet JP, Thiele H, Barbato E. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289-1367
• 3 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
• 4 Silvain J, Lattuca B, Beygui F. et al. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet 2020; 396: 1737-1744
• 5 Mauri L, Kereiakes DJ, Yeh RW. et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-2166
• 6 Bonaca MP, Bhatt DL, Cohen M. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800
• 7 Bonaca MP, Bhatt DL, Storey RF. et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol 2016; 67: 2719-2728
• 8 Eikelboom JW, Connolly SJ, Bosch J. et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377: 1319-1330
• 9 Mehran R, Baber U, Sharma SK. et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med 2019; 381: 2032-2042
• 10 Watanabe H, Morimoto T, Natsuaki M. et al. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol 2022; 7: 407-417
• 11 Valgimigli M, Frigoli E, Heg D. et al. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N Engl J Med 2021; 385: 1643-1655
• 12 Angiolillo DJ, Galli M, Collet JP. et al. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention 2022; 17: e1371-e1396